NewsEuropeSuppliers Selected For Ireland’s Medical Cannabis Pilot

Suppliers Selected For Ireland’s Medical Cannabis Pilot

-

TWO companies have been approved as the first suppliers to Ireland’s recently launched medical cannabis programme.

The Irish Government signed off on the launch of its five-year pilot in June, with Canadian firm Aurora and MGC Pharmaceuticals, of Australia, selected to provide its first cannabis medicine.

Under the scheme consultants can prescribe to patients for spasticity, associated with multiple sclerosis, chemotherapy-related intractable nausea and treatment-resistant epilepsy.

The two products are Aurora High CBD Oil Drops and CannEpil, both are CBD based drugs with the latter being used to treat epilepsy.

However, much like its UK neighbour there will be a time-lag of weeks between prescription and receipt of the drug.

The Irish Journal reports that under the scheme the two companies have to apply for a licence to bring the product into Ireland for distribution. 

CannEpil is a product that ‘has been years in the making’, and was released into the market in 2017, says Roby Zomer, Executive Director and CEO at MGC. 

The Medical Cannabis Access Programme was signed into law in June this year, by Ireland’s Minister for Health, Simon Harris. 

Mr Harris said at the time that the programme would allow ‘compassionate access to cannabis for medical reasons’ in cases where conventional treatment has failed.

The Irish Government says it wants to encourage the development of a home-grown cannabis cultivation and hemp industry saying it the potential to create over 80,000 jobs.

Peter
Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

Latest news

MGC Pharmaceuticals Releases Update On CimetrA Clinical Trial Progress In USA

MGC Pharmaceuticals Ltd (ASX, LSE: MXC, ‘MGC Pharma’ or ‘the Company’), a European based bio-pharma company specialising in the production and development...

European Cannabis Stocks Review: Akanda’s ‘Concerned Shareholders’ Oust All Directors Except CEO To Prevent ‘Potentially Irreparable Harm’ – More From Goodbody Health & Chill...

It has been another week of positive developments for the cannabis industry across Europe, with yet more markets making...

Analysis Shows UK Market Could Grow To Over £1bn By 2026 As London Prepares To Host Europe’s Leading Cannabis Conference

ANALYSIS shows UK market could grow to over £1bn by 2026 as London prepares to host Europe’s leading cannabis...

Medical Cannabis Could Be Available In Spain By The End Of The Year

SPAIN could now see the regulation and distribution of medical cannabis rolled out before the end of the year...

New UK Company Heralds Its ‘Unique’ Medical Cannabis Delivery Mechanism

CANNABIS extraction and formulations specialist 113 Botanicals is in the process of securing Good manufacturing Practice (GMP) compliance for...

German Cannabis Bill By Year End With Adult-Use Launch Likely In Early 2024

GERMANY’s draft cannabis law should be ready by the end of the year with the launch of its adult-use...

Must read

You might also likeRELATED
Recommended to you